case_images: PMC9459224_01
case_images: (A-D) The enhanced computed tomography (enhanced-CT) scans of the tumor before neoadjuvant therapy. (E-H) The enhanced-CT scans of the tumor after three cycles of neoadjuvant therapy.
case_images: fimmu-13-989966-g001.jpg
case_images: PMC9459224_01_fimmu-13-989966-g001.jpg
case_images: f1
case_images: The computed tomography (CT) scans showed that the malignant lesion, located between the left upper and lower lobes, had invaded the left pulmonary artery ( Figure 1 ).
case_images: (A, B) TEN and rash induced by sintilimab in the patient with advanced NSCLC. (C, D) An image of the skin after recovery from severe TEN.
case_images: fimmu-13-989966-g002.jpg
case_images: PMC9459224_01_fimmu-13-989966-g002.jpg
case_images: f2
case_images: The cutaneous lesions accounted for approximately 95% of the whole body surface ( Figure 2 ).
case_images: Anti-tuberculosis therapy: Isoniazid (300 mg per day), Rifampicin (450 mg per day), Ethambutol (750 mg per day), Pyrazinamide (1250 mg per day). Neoadjuvant therapy: Sintilimab (200 mg) plus platinum-based conventional chemotherapy (paclitaxel and cisplatin). PR, Partial response; TEN, Toxic epidermal necrolysis; AE, Adverse event.
case_images: fimmu-13-989966-g003.jpg
case_images: PMC9459224_01_fimmu-13-989966-g003.jpg
case_images: f3
case_images: TEN without any adverse events. The timeline of the treatment of the patient was presented in  Figure 3 .